New Crowdfunding Site Allows Public to Advance U.Va. Research Projects Through Targeted Donations
CHARLOTTESVILLE, VA - U.Va. Innovation launched the University of Virginia’s first crowdfunding website this week, enabling alumni and others to make targeted, tax-deductible donations in support of specific research and development projects under way at the University. “The University of Virginia is among the very first institutions of higher education to use philanthropic crowdfunding to advance university research,” said Thomas C. Skalak, vice president for research at U.Va. “It’s our hope that this innovative initiative will build on the success of the University’s...
Read MoreArea celebrates 10 years of biotechnology advances
ALACHUA, FL — Imagine a future where every time you take your medications, your body sends a message to your doctor. And your doctor also would know when you don’t take them. This medical message in a bottle would come in an ibuprofen-sized capsule lined with wiring that would send a signal to your doctor that starts after you swallow the medication and it hits your gastric juices. Inventions like this one — from Newberry-based company “etect” — are being developed, as the saying goes, right in our backyard. But if you live in Gainesville, you’re entitled to...
Read MoreHeat Biologics files $20M public stock offering
CHAPEL HILL, NC - Chapel Hill drug development company Heat Biologics has filed to go public, joining a slew of companies such as Quintiles (NYSE: Q), Liposcience (Nasdaq: LPDX), PlyGem and Chimerix (Nasdaq: CMRX) to take the plunge in 2013. The small company, characterized as an “emerging growth” business under the JOBS Act plans to raise about $20 million in the offering and trade on Nasdaq under the symbol “HEAX.” Heat’s technology platform aims to trigger a patient’s own cells in fighting cancer — an alternative to side effect-heavy chemotherapy. The company has...
Read MoreQuintiles Announces Pricing of Initial Public Offering
RESEARCH TRIANGLE PARK, N.C.- Quintiles today announced the pricing of its initial public offering of 23,684,210 shares of its common stock at a price to the public of $40.00 per share. The shares of Quintiles common stock are expected to begin trading on the New York Stock Exchange under the single-letter symbol “Q” on May 9, 2013. Quintiles is offering 13,125,000 shares of common stock, and selling shareholders are offering 10,559,210 shares of common stock. In addition, the selling shareholders have granted the underwriters a 30-day option to purchase up to an additional 3,552,631...
Read MoreNew company springs from nanotech Liquidia
DURHAM, NC - Nanotechnology firm Liquidia Technologies is spinning out a new ophthalmology-focused company, building on the success of a recent partnership with GlaxoSmithKline (NYSE: GSK). Last year, an agreement with GSK regarding Liquidia’s vaccine and pulmonary technology paved a cash runway for other possibilities with the platform. CEO Neal Fowler released the following statement today: “Liquidia has had the great fortune of being able to demonstrate how our transformative product development and manufacturing platform can be applied to the development of very promising...
Read MoreBioFlorida names Bryan CEO
WEST PALM BEACH, FL – BioFlorida, the advocate for the state’s life sciences industry, named Nancy Bryan as president and CEO. She replaces Russell Allen, who left to become the head of Georgia Bio. The West Palm Beach-based organization selected Bryan after conducting a national search. She’s been in the industry for more than 25 years, including positions as senior vice president of commercial operations at NPS Pharmaceuticals, senior vice president of marketing and sales for Indevus Pharmaceuticals and head of commercial operations at Elan Pharmaceuticals for the global...
Read More
![[Valid RSS]](valid-rss-rogers.png "Validate my RSS feed")
Follow Us!